The identification of BRCA mutations plays a crucial role in the management of hereditary cancer prevention and treatment. Nonetheless, BRCA-testing in pancreatic cancer (PC) patients is not universally introduced in clinical practice. A retrospective analysis was conducted, firstly, to evaluate the rate of BRCA-positive families among those presenting a family history of PC besides breast and/or ovarian cancer. Secondly, the relationship between BRCA pathogenic variants and PC risk was evaluated. Finally, the characteristics of PC developed in BRCA families were described. Among 5143 family trees reporting breast and/or ovarian cancer cases, 392 showed a family history of PC. A total of 35 families (24.5% selected by the Modena Criteria and 21.3% by the NCCN Criteria) were positive to BRCA testing. Among the BRCA1 mutations, 36.8% were found within a region defined by c.3239–c.3917, whilst 43.7% of BRCA2 mutations were located within c.7180–c.8248. This study confirmed that an increase in the rate of positive tests in families with PC when associated to breast and/or ovarian tumors. Moreover, this analysis indicated two possible Pancreatic Cancer Cluster Regions that should be verified in future research. Finally, PC in families with breast and/or ovarian cancer history, particularly in BRCA families, were diagnosed at younger age and showed better one-year overall survival.

Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies / Toss, Angela; Venturelli, Marta; Molinaro, Eleonora; Pipitone, Stefania; Barbieri, Elena; Marchi, Isabella; Tenedini, Elena; Artuso, Lucia; Castellano, Sara; Marino, Marco; Tagliafico, Enrico; Razzaboni, Elisabetta; De Matteis, Elisabetta; Cascinu, Stefano; Cortesi, Laura. - In: CANCERS. - ISSN 2072-6694. - 11:2(2019), pp. 193-203. [10.3390/cancers11020193]

Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies

Toss, Angela;Venturelli, Marta;Molinaro, Eleonora;Pipitone, Stefania;Tenedini, Elena;Artuso, Lucia;CASTELLANO, SARA;Marino, Marco;Tagliafico, Enrico;Razzaboni, Elisabetta;De Matteis, Elisabetta;Cascinu, Stefano;
2019

Abstract

The identification of BRCA mutations plays a crucial role in the management of hereditary cancer prevention and treatment. Nonetheless, BRCA-testing in pancreatic cancer (PC) patients is not universally introduced in clinical practice. A retrospective analysis was conducted, firstly, to evaluate the rate of BRCA-positive families among those presenting a family history of PC besides breast and/or ovarian cancer. Secondly, the relationship between BRCA pathogenic variants and PC risk was evaluated. Finally, the characteristics of PC developed in BRCA families were described. Among 5143 family trees reporting breast and/or ovarian cancer cases, 392 showed a family history of PC. A total of 35 families (24.5% selected by the Modena Criteria and 21.3% by the NCCN Criteria) were positive to BRCA testing. Among the BRCA1 mutations, 36.8% were found within a region defined by c.3239–c.3917, whilst 43.7% of BRCA2 mutations were located within c.7180–c.8248. This study confirmed that an increase in the rate of positive tests in families with PC when associated to breast and/or ovarian tumors. Moreover, this analysis indicated two possible Pancreatic Cancer Cluster Regions that should be verified in future research. Finally, PC in families with breast and/or ovarian cancer history, particularly in BRCA families, were diagnosed at younger age and showed better one-year overall survival.
11
2
193
203
Hereditary pancreatic cancer: A retrospective single-center study of 5143 Italian families with history of BRCA-related malignancies / Toss, Angela; Venturelli, Marta; Molinaro, Eleonora; Pipitone, Stefania; Barbieri, Elena; Marchi, Isabella; Tenedini, Elena; Artuso, Lucia; Castellano, Sara; Marino, Marco; Tagliafico, Enrico; Razzaboni, Elisabetta; De Matteis, Elisabetta; Cascinu, Stefano; Cortesi, Laura. - In: CANCERS. - ISSN 2072-6694. - 11:2(2019), pp. 193-203. [10.3390/cancers11020193]
Toss, Angela; Venturelli, Marta; Molinaro, Eleonora; Pipitone, Stefania; Barbieri, Elena; Marchi, Isabella; Tenedini, Elena; Artuso, Lucia; Castellano, Sara; Marino, Marco; Tagliafico, Enrico; Razzaboni, Elisabetta; De Matteis, Elisabetta; Cascinu, Stefano; Cortesi, Laura
File in questo prodotto:
File Dimensione Formato  
cancers-11-00193-v2.pdf

accesso aperto

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 812.52 kB
Formato Adobe PDF
812.52 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1175878
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 13
  • ???jsp.display-item.citation.isi??? 11
social impact